tirzepatide and chronic kidney disease (Zepbound) showed improved function in obese patients with both kidney #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Effects of tirzepatide on circulatory
Description
In a phase 1 trial, a PYY analogue (Y14 peptide) administered subcutaneously at 7- to 14-days intervals was safe and potentially efficacious (WL between 2.9 and 3.6 kg at 31 days, with a 3855% reduction in food intake vs
This is not an arbitrary decision
Learn how GLP-1 medications work and talk with our provider to determine whether standard dosing or microdosing is the best fit for your goals
Strategies like protein pacing can be valuable for streamlining nutrition, ensuring you hit your quotas
